IBA SA - basic data - update following capital increase dated 22 September 2016 (SOP)
23 Septembre 2016 - 10:19AM
IBA -
Data concerning transparency
Louvain-la-Neuve,
Belgium, September 22, 2016 - IBA (Ion Beam Applications SA),
the world's leading provider of proton therapy solutions for the
treatment of cancer, communicates today the basic and additional
data as per Article 15 §1 al.1 of the Transparency Law, following
its capital increase (further to exercises of stock options) dated
September 22, 2016.
Data concerning
transparency
Heading II of the law of May 2, 2007 and the Royal
Decree of February 14, 2008
Communication of the basic data as per Article 15
§1 al.1 of the Law
-
Total capital:
EUR 41 524 753,70
-
Total number of securities conferring the voting
right:
29 585 703 (of which 12 702 489 with VVPR
strips)
-
Total number of voting rights (= the
denominator):
29 585 703
-
Total number of securities conferring the voting
right, by category: N/A
-
Total number of voting rights, by
category:
N/A
Communication of the additional data as per
Article 15 §1 al.2 of the Law
-
Total number of convertible bonds conferring the
voting right:
0
-
Total number of rights, materialized or not by
certificates, giving the
right to subscribe to newly issued securities conferring the voting
right
(e.g.
warrants):
801 676
-
Total number of voting rights which would result
from the exercise of
these conversion or subscription
rights:
801 676
-
Total number of shares without voting right:
0
Statutory thresholds as per Article 18 of the
Law
The applicable thresholds as follows: three
percent, five percent, ten percent, fifteen percent and so on by
brackets of five percent.
*
*
*
*
About
IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room systems. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,400 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European
stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB).
More information can be found at:
www.iba-worldwide.com .
For more
information, please contact
IBA
Caroline Hardy
Corporate Legal Counsel
+32 10 201 159
caroline.hardy@iba-group.com
20160922 evolution of the basic
data EN
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024